Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million on August 18, 2023. In similar transaction Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million. Qingdao Laoshan District Finance Bureau and Qingdao State-owned Assets Supervision and Administration Commission, approved for Huilong Huaze to acquire 9,720,000 shares in Hangzhou TianMuShan from Yongxin Huarui.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.22 CNY | -0.48% | -2.38% | -29.50% |
1st Jan change | Capi. | |
---|---|---|
-29.50% | 139M | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- 600671 Stock
- News Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
- Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million.